• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Lotensin HCT (benazepril/hydrochlorothiazide) tablets

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – November 2009

 

Summary View

 

CONTRAINDICATIONS

  • Lotensin is also contraindicated in patients with a history of angioedema with or without previous ACE inhibitor treatment.

ADVERSE REACTIONS

Skin
  • Erythema multiforme including Steven-Johnson syndrome, exfoliative dermatitis, including toxic epidermal necrolysis